ANTI-TSG101 (C-TERMINAL)

Suggested starting dilutions are as follows: WB: 1:500-1:3000. Suggested fixation for ICC/IF: 3-3.5% PFA with 0.05% saponin treatment. Not yet tested in other applications. Optimal working dilutions should be determined experimentally by the end user.
Monoclonal Anti-TSG101 antibody has been used in western blotting and immunoprecipitation (IP) analyses.

Tumor susceptibility gene 101 protein (TSG101) is mapped to human chromosome 11p15.1. TSG101 has ubiquitin E2 variant domain.

Tumor susceptibility gene 101 protein (TSG101) is a component of endosomal sorting complex required for transport (ESCRT) machinery. TSG101 interacts with arrestin domain-containing protein 1 and mediates its budding through plasma membrane. It binds to ubiquitinylated proteins and conveys them for degradation by lysosomes. TSG101 is also essential for the budding human immunodeficiency virus (HIV) infected cells. TSG101 deficiency is associated with genome instability and is considered as a risk factor for tumor initiation.